Showing 1921-1930 of 2526 results for "".
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- Reichert Celebrates 100-Year Anniversary of the First Phoroptor Refracting Instrument Modelhttps://modernod.com/news/reichert-celebrates-100-year-anniversary-of-the-first-phoroptor-refracting-instrument-model/2480918/Reichert Technologiea, a business unit of Ametek, celebrated the 100-year anniversary of the first Phoroptor Refracting Instrument model. Released in 1922, this instrument helped transform eye care with its revolutionary ability to provide practitioners a better, faster, and more effici
- Prevent Blindness and Aerie Pharmaceuticals Partner to Offer New Glaucoma Research Granthttps://modernod.com/news/prevent-blindness-and-aerie-pharmaceuticals-partner-to-offer-new-glaucoma-research-grant/2480868/Research to Prevent Blindness (RPB) and Aerie Pharmaceuticals are partnering to provide early- to mid-career vision scientists with opportunities to pursue glaucoma research of unusual significance and promise. RPB announced the launch the RPB/David L. Epstein Career Advancem
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to Iluvien Use for IOP Outcomeshttps://modernod.com/news/phase-4-paladin-study-confirms-positive-predictive-value-of-corticosteroid-course-prior-to-iluvien-use-for-iop-outcomes/2480855/Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the Iluvien U.S. label to mitigate the risk of uncontrolled IOP elevation. These results were presented at the annual Association for Researc
- Bausch + Lomb Corporation Launches as a Publicly Traded Companyhttps://modernod.com/news/bausch-lomb-corporation-launches-as-a-publicly-traded-company/2480851/Bausch + Lomb Corporation today launched as a publicly traded company focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the “BLCO” symbol on the New York Stock Exchange and Toronto Stock Exchange.1
- Zeiss Offers New SLT Application for the Visulas Green Therapeutic Laserhttps://modernod.com/news/zeiss-offers-new-slt-application-for-the-visulas-green-therapeutic-laser/2480842/Zeiss Medical Technology announced that it now offers the new SLT add-on to its Visulas green laser, part of an integrated glaucoma workflow designed to advance safe and effective glaucoma treatment. The new SLT laser feature offers unique protocols that may im
- SAV-IOL Launches Instant Focus EDOF IOL Technologyhttps://modernod.com/news/sav-iol-launches-instant-focus-edof-iol-technology/2480841/Instant Focus is a unique optical technology designed by Swiss IOL maker SAV-IOL (Swiss Advanced Vision). The technology is designed to replace the accommodative function of the eye’s natural lens after cataract surgery, and is manufactured and marketed directly from their he
- Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-new-commercial-and-medicare-coverage-for-eysuvis/2480834/Kala Pharmaceuticals announced that the largest Pharmacy Benefit Manager in the United States has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million people to Eysuvis coverage,
- Théa Introduces iVIZIA OTC Eye Care Products in UShttps://modernod.com/news/thea-introduces-ivizia-otc-eye-care-products-in-us/2480796/Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA